|
Carlo Gambacorti-Passerini (born 1957) is an Italian oncologist and hematologist known for his contributions to cancer research. He is Professor of Internal Medicine and Hematology at the University of Milan Bicocca in Italy and Director of the Clinical Research Unit at S. Gerardo Hospital, Monza, Italy. He was Senior Investigator and Head of the Oncogenic Fusion Proteins Unit at the National Cancer Institute, Milan Italy from 1990 to 2003, and Professor of Oncology and Hematology at McGill University, Montreal, Canada, from 2004 to 2007. His main scientific contribution relates to the preclinical and clinical development of imatinib.〔 〕 His publications between 1997 and 2000 are among the earliest original reports on this revolutionary drug. Specifically, he showed that apoptosis, or programmed cell death, was the predominant mechanism through which imatinib eliminates leukemic cells, that leukemic animals could be cured using imatinib, and that resistance to imatinib could be mediated by gene amplification of BCR-ABL1. Dr. Gambacorti-Passerini is the Chairman of the ILTE (Imatinib Long Term side Effects) study,〔 (【引用サイトリンク】title=ILTE study page )〕 an independent clinical study aimed at assessing the long-term effects of imatinib in 948 CML patients worldwide, which showed for the first time that CML patients in remission have a normal life expectancy.〔 〕 He is also the first researcher who (in June 2010) successfully treated a patient affected by ALK+ lymphoma with an ALK inhibitor (crizotinib).〔Gambacorti-Passerini C et al. "Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients". ''2010 Annual Meeting of the American Society of Hematology'', Orlando, Florida〕〔 〕 In 2012 Dr. Gambacorti-Passerini discovered ''SETBP1'' as a novel oncogene and identified specific mutations of this gene in patients affected by atypical Chronic Myeloid Leukemia (aCML). ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Carlo Gambacorti-Passerini」の詳細全文を読む スポンサード リンク
|